Please select a video from the list below.
Selexipag for the Treatment of Connective Tissue Disease-Associated PAH
This program reviews the recent publication by Gaine et al (Eur Respir J, 2017) regarding use of the novel prostacyclin receptor agonist, selexipag, in patients with connective tissue disease related pulmonary hypertension. This review, by paper co-author Dr. Richard Channick examines the essential efficacy and safety of this drug in a group of patients considered hard-to-treat.
Recent Video
Most Viewed
Specialties :                    Search :
RESPITE Study Results
RESPITE Study Results Views - 1028
ICU Management of PH
ICU Management of PH Views - 149